Bajema I, Rijnink E. Idiopathic nonlupus full-house nephropathy. In: Colvin RB, Chang A, editors. Diagnostic pathology kidney diseases. 3rd ed. Philadelphia: Elsevier; 2015. p. 190–1.

Google Scholar 

Gianviti A, Barsotti P, Barbera V, Faraggiana T, Rizzoni G. Delayed onset of systemic lupus erythematosus in patients with “full-house” nephropathy. Pediatr Nephrol. 1999;13(8):683–7.

Article  CAS  PubMed  Google Scholar 

Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones E, Magil A. Nonsystemic mesangiopathic glomerulonephritis with “full house” immunofluorescence: pathological and clinical observations in five patients. Am J Clin Pathol. 1982;78(1):29–34.

Article  CAS  PubMed  Google Scholar 

Miura M, Tomino Y, Nomoto Y, Endoh M, Suga T, Kaneshige H, et al. IgA nephropathy with “Full House” immunofluorescence. Am J Clin Pathol. 1983;79(2):273.

Article  CAS  PubMed  Google Scholar 

Rijnink EC, Teng YK, Kraaij T, Wolterbeek R, Bruijn JA, Bajema IM. Idiopathic non-lupus full-house nephropathy is associated with poor renal outcome. Nephrol Dial Transpl. 2017;32(4):654–62.

Article  CAS  Google Scholar 

Wen YK, Chen ML. Clinicopathological study of originally non-lupus “full-house” nephropathy. Ren Fail. 2010;32(9):1025–30.

Article  PubMed  Google Scholar 

Hongyan L, Yi Z, Bao D, Yuewu L, Juan M. A study on clinical and pathologic features in lupus nephritis with mainly IgA deposits and a literature review. Clin Dev Immunol. 2013;2013: 289316.

Article  PubMed  PubMed Central  Google Scholar 

Medjeral-Thomas NR, Cook HT, Pickering MC. Complement activation in IgA nephropathy. Semin Immunopathol. 2021;43(5):679–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haas M. IgA nephropathy and iga vasculitis henoch-schönlein purpura nephritis. In: Jennette JC, Olson JL, Silva FG, D’Agati VD, editors. Heptinstalls pathology of the kidney. 7th ed. Philadelphia: Wolters Kluwer; 2015. p. 463–525.

Google Scholar 

Rizk DV, Maillard N, Julian BA, Knoppova B, Green TJ, Novak J, et al. The emerging role of complement proteins as a target for therapy of iga nephropathy. Front Immunol. 2019;19(10):504.

Article  Google Scholar 

Renner B, Laskowski J, Poppelaars F, Ferreira VP, Blaine J, Antonioli AH, et al. Factor H related proteins modulate complement activation on kidney cells. Kidney Int. 2022;102(6):1331–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cantsilieris S, Nelson BJ, Huddleston J, Baker C, Harshman L, Penewit K, et al. Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (CFH) gene family. Proc Natl Acad Sci U S A. 2018;115(19):E4433–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. 2006;38(10):1173–7.

Article  CAS  PubMed  Google Scholar 

Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7(5): e1002079.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3(3): e41.

Article  PubMed  PubMed Central  Google Scholar 

Nozawa A, Ozeki M, Hori T, Kawamoto N, Hirayama M, Azuma E, et al. A heterozygous CFHR3-CFHR1 gene deletion in a pediatric patient with transplant-associated thrombotic microangiopathy who was treated with eculizumab. J Pediatr Hematol Oncol. 2018;40(8):e544–6.

Article  CAS  PubMed  Google Scholar 

Freyer CW, Bange EM, Skuli S, Hsu M, Lin J, Cuker A, et al. Carfilzomib-induced atypical hemolytic uremic syndrome in a patient with heterozygous CFHR3/CFHR1 deletion treated with eculizumab. Clin Lymphoma Myeloma Leuk. 2021;21(11):e845–9.

Article  CAS  PubMed  Google Scholar 

Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43(4):321–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu L, Zhai YL, Wang FM, Hou P, Lv JC, Xu DM, et al. Variants in complement factor h and complement factor h-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol. 2015;26(5):1195–204.

Article  CAS  PubMed  Google Scholar 

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8(6): e1002765.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jullien P, Laurent B, Claisse G, Masson I, Dinic M, Thibaudin D, et al. Deletion variants of cfhr1 and cfhr3 associate with mesangial immune deposits but not with progression of iga nephropathy. J Am Soc Nephrol. 2018;29(2):661–9.

Article  CAS  PubMed  Google Scholar